I. Boukovinas

4.5k total citations
14 papers, 170 citations indexed

About

I. Boukovinas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, I. Boukovinas has authored 14 papers receiving a total of 170 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 3 papers in Gastroenterology. Recurrent topics in I. Boukovinas's work include Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (4 papers) and Lung Cancer Treatments and Mutations (4 papers). I. Boukovinas is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (4 papers) and Lung Cancer Treatments and Mutations (4 papers). I. Boukovinas collaborates with scholars based in Greece, France and United States. I. Boukovinas's co-authors include Alexandros Ardavanis, P. Kosmidis, M. Veslemes, Ph. Palamidas, Aristidis Polyzos, Ch. Kouroussis, M. Toubis, Jean‐Yves Blay, Athina Agelidou and Ioannis G. Vlachonikolis and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

I. Boukovinas

14 papers receiving 163 citations

Peers

Countries citing papers authored by I. Boukovinas

Since Specialization

Citations

This map shows the geographic impact of I. Boukovinas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Boukovinas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Boukovinas more than expected).

Fields of papers citing papers by I. Boukovinas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Boukovinas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Boukovinas. The network helps show where I. Boukovinas may publish in the future.

Co-authorship network of co-authors of I. Boukovinas

This figure shows the co-authorship network connecting the top 25 collaborators of I. Boukovinas. A scholar is included among the top collaborators of I. Boukovinas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Boukovinas. I. Boukovinas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers 2023 ·Journal of Clinical Medicine ·Stefania Kokkali, Anastasios Kyriazoglou, (unknown), Panagiota Economopoulou, (unknown), Amanda Psyrri, Alexandros Ardavanis, Nikolaos Vassos, I. Boukovinas	7
2	A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients’ Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece 2022 ·Cancers ·Stefania Kokkali, I. Boukovinas, E. Samantas, Pavlos Papakotoulas, Ilias Athanasiadis, C. Andreadis, (unknown), G.F. Samelis, Eleni Timotheadou, (unknown), Christos Papadimitriou, (unknown), Alexandros Ardavanis, Ioannis Kotsantis, (unknown), (unknown), Amanda Psyrri	3
3	Challenges in sarcoidosis and sarcoid‐like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case 2020 ·Dermatologic Therapy ·Zoé Apalla, (unknown), Chryssoula Papageorgiou, Mattheos Bobos, (unknown), Christina Fotiadou, (unknown), I. Boukovinas, (unknown), (unknown), Aimilios Lallas, Elizabeth Lazaridou	21
4	Recurrence-free Survival and Safety of Imatinib in Patients With Gastrointestinal Stromal Tumour (GIST) in Greece 2019 ·Anticancer Research ·I. Boukovinas, Αthanasios Kotsakis, Nikolaos Androulakis, Gerasimos Aravantinos, Vasiliki Michalaki, Christos Christodoulou, (unknown), Christos N. Papandreou, (unknown), (unknown), P. Kosmidis	2
5	Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy) 2017 ·Annals of Oncology ·Axel Grothey, Alberto Sobrero, Jeffrey A. Meyerhardt, Takayuki Yoshino, James Paul, Julien Taı̈eb, Ioannis Souglakos, Richard Kerr, Roberto Labianca, Anthony F. Shields, Franck Bonnetain, Takeharu Yamanaka, I. Boukovinas, Qian Shi, (unknown), Donna Niedzwiecki, Valter Torri, Daniel J. Sargent, Thierry André, Timothy Iveson	3
6	The Management and Costs of Locally Advanced or Metastatic Alk-Positive Non-Small Cell Lung Cancer in Greece 2015 ·Value in Health ·(unknown), I. Boukovinas, Vassilis Georgoulias, P. Kosmidis, George Koumakis, (unknown), E. Samantas, Konstantinos Syrigos, Dimitrios Krikelis, (unknown), Mary Geitona	1
7	Cost-Effectiveness Analysis of Panitumumab+Mfolfox over Bevacizumab+Mfolfox as a First-Line Treatment for Metastatic Colorectal Cancer Patients with Wild-Type Ras in Greece 2014 ·Value in Health ·Georgia Kourlaba, I. Boukovinas, Zenia Saridaki, (unknown), (unknown), Nikos Maniadakis	4
8	Adjuvant therapy in primary GIST: state-of-the-art 2012 ·Annals of Oncology ·Peter Reichardt, Jean‐Yves Blay, I. Boukovinas, Thomas Brodowicz, (unknown), Paolo G. Casali, M. Decatris, Mats Eriksson, Hans Gelderblom, P. Kosmidis, Axel Le Cesne, (unknown), M. Schlemmer, Jaap Verweij, Heikki Joensuu	50
9	Changes in cancer tissue induced by treatment with bevacizumab in metastatic breast cancer. 2010 ·Journal of Clinical Oncology ·Georgios Kesisis, (unknown), E. Yiannaki, (unknown), (unknown), (unknown), I. Boukovinas, (unknown), Alexandros Kortsaris, Konstantinos Papazisis	2
10	Sequential administration of cisplatin (c), gemcitabine (g) and docetaxel (d), as first-line treatment in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract: A multicenter phase II study 2006 ·Journal of Clinical Oncology ·Nikolaos Androulakis, I. Boukovinas, V. Bozionelou, A. Kalykaki, Anna Potamianou, Athanasios Pallis, L. Vamvakas, (unknown), Ioannis Souglakos, (unknown)	1
11	Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study 2004 ·British Journal of Cancer ·Vassilis Georgoulias, Ch. Kouroussis, Athina Agelidou, I. Boukovinas, Ph. Palamidas, (unknown), Aristidis Polyzos, K. Syrigos, M. Veslemes, M. Toubis, Alexandros Ardavanis, (unknown), Ioannis G. Vlachonikolis	51
12	Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group 2004 ·Journal of Clinical Oncology ·P. Kosmidis, Meletios Α. Dimopoulos, (unknown), C. Nicolaides, Gerasimos Aravantinos, I. Boukovinas, D. Pectasides, D. Bafaloukos, M. Karina, Haralabos P. Kalofonos	11
13	Gemcitabine (G) vs gemcitabine-carboplatin (GCB) for patients with advanced non-small cell lung cancer (NSCLC) and PS:2. A prospective randomized phase II study of the Hellenic Co-Operative Oncology Group 2004 ·Journal of Clinical Oncology ·P. Kosmidis, Meletios Α. Dimopoulos, (unknown), C. Nicolaides, Gerasimos Aravantinos, I. Boukovinas, D. Pectasides, D. Bafaloukos, M. Karina, Haralabos P. Kalofonos	6
14	[Gastro-intestinal stromal tumors: news and comments]. 2003 ·PubMed ·Isabelle Ray‐Coquard, Axel Le Cesne, (unknown), I. Boukovinas, Dominique Ranchère, Philippe Thiesse, Vincent Baty, Jean‐Yves Blay	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact